AMENDMENT

In the Claims

This listing of claims will replace all prior versions and listings of claims.

1-26. (Canceled)

27. (Previously Presented) A method for delivery of one or more cytokines comprising administering to a human or animal a composition comprising one or more cytokines and a target molecule admixed with or bound to a colloidal metal.

28. (Currently Amended) The method of Claim 27, wherein the one or more cytokines are selected from the group consisting of Interleukin-1a ("IL-1*a*"), Interleukin-1B ("IL-1β"), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, and Granulocyte CSF.[,]

29. (Previously Presented) A method for the targeted delivery of one or more chemotherapeutic agents, comprising administering to a human or animal a composition comprising one or more chemotherapeutic agents and a target molecule admixed with or bound to colloidal metal.

30. (Currently Amended) A method for ~~of~~ the delivery of ~~delivering~~ one or more biological factors comprising administering to a human or animal a composition comprising one or more biologically active factors and a target molecule admixed with or bound to a

colloidal metal, wherein the biologically active factor is selected from the group consisting of lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF*a*"), transforming growth factor beta ("TGF β"), heat shock proteins, carbohydrate moieties of blood groups, RH factors, fibroblast growth factor, AZT, cancer cell specific antigens, hormones, antibodies, antibiotics, anti-virals and immunotherapeutic drugs.

31. (Currently Amended) The method of Claim 27, wherein the target molecule is selected from the group consisting of Tumor Necrosis Factor ("TNF*a"*), Transforming Growth Factor-β ("TGFβ), Migration Inhibition Factor, vascular epithelial growth factor ("VEGF"), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polycolonal antibodies, cancer cell specific antigen, and transforming growth factor alpha ("TGF*a*").

32-34. (Canceled)

35. (Previously Presented) The method of claim 29 wherein the target molecule is selected from the group consisting of Interleukin-1a ("IL-1*a*"), Interleukin-1B ("IL-1β"), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Tumor Necrosis Factor ("TNF*a"*) Transforming Growth Factor-β ("TGFβ), Migration Inhibition Factor, vascular epithelial growth factor ("VEGF"), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polycolonal antibodies, cancer cell specific antigens, and transforming growth factor alpha ("TGF*a*").

36. (Previously Presented) The method of claim 35, wherein the target molecule is TNF*a*.

37. (Withdrawn) The method of claim 35, wherein the target molecule is a cancer cell specific antigen.

38. (Withdrawn) The method of claim 37, wherein the cancer cell specific antigen is MART, MAGE, or BAGE.

39. (Withdrawn) The method of claim 35, wherein the targeting molecule is a polyclonal or monoclonal antibody.

40. (Withdrawn) The method of claim 31, wherein the target molecule is a cancer cell specific antigen.

41. (Withdrawn) The method of claim 41, wherein the cancer cell specific antigen is MART, MAGE, or BAGE.

42. (Withdrawn) The method of claim 31, wherein the target molecule is a polyclonal or monoclonal antibody.

43. (Previously Presented) The method of claim 30, wherein the target molecule is selected from the group consisting of Interleukin-1a ("IL-1*a*"), Interleukin-1B ("IL-1β"), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Tumor Necrosis Factor ("TNF*a*") Transforming Growth Factor-β ("TGFβ), Migration Inhibition Factor, vascular epithelial growth factor ("VEGF"), receptor proteins, glucose, glycogen, phospholipids,

monoclonal and/or polycolonal antibodies, a bacterial coat protein, a cancer cell specific antigen, and transforming growth factor alpha ("TGF*a*").

44. (Previously Presented) The method of claim 43, wherein the targeting molecule is TNF*a*.

45. (Withdrawn) The method of claim 43, wherein the target molecule is a cancer cell specific antigen.

46. (Withdrawn) The method of claim 45, wherein the cancer cell specific antigen is MART, MAGE or BAGE.

47. (Withdrawn) The method of claim 43, wherein the target molecule is IL-2 and the biologically active factor is an anti-viral compound.

48. (Withdrawn) The method of claim 43, wherein the target molecule is a bacterial coat protein and the biologically active agent is an antibiotic.